Pancreatic adenocarcinoma, Version 2.2021

Margaret A. Tempero; Mokenge P. Malafa; Mahmoud Al-Hawary; Stephen W. Behrman; Al B. Benson; Dana B. Cardin; E. Gabriela Chiorean; Vincent Chung; Brian Czito; Marco Del Chiaro; Mary Dillhoff; Timothy R. Donahue; Efrat Dotan; Cristina R. Ferrone; Christos Fountzilas; Jeffrey Hardacre; William G. Hawkins; Kelsey Klute; Andrew H. Ko; John W. Kunstman; Noelle LoConte; Andrew M. Lowy1; Cassadie Moravek; Eric K. Nakakura; Amol K. Narang; Jorge Obando; Patricio M. Polanco; Sushanth Reddy; Marsha Reyngold; Courtney Scaife; Jeanne Shen; Charles Vollmer; Robert A. Wolff; Brian M. Wolpin; Beth Lynn; Giby V. George

doi:10.6004/jnccn.2021.0017

Pancreatic adenocarcinoma, Version 2.2021

Margaret A. Tempero, Mokenge P. Malafa, Mahmoud Al-Hawary, Stephen W. Behrman, Al B. Benson, Dana B. Cardin, E. Gabriela Chiorean, Vincent Chung, Brian Czito, Marco Del Chiaro, Mary Dillhoff, Timothy R. Donahue, Efrat Dotan, Cristina R. Ferrone, Christos Fountzilas, Jeffrey Hardacre, William G. Hawkins, Kelsey Klute, Andrew H. Ko, John W. KunstmanNoelle LoConte, Andrew M. Lowy1, Cassadie Moravek, Eric K. Nakakura, Amol K. Narang, Jorge Obando, Patricio M. Polanco, Sushanth Reddy, Marsha Reyngold, Courtney Scaife, Jeanne Shen, Charles Vollmer, Robert A. Wolff, Brian M. Wolpin, Beth Lynn, Giby V. George

Research output: Contribution to journal › Review article › peer-review

500 Scopus citations

Abstract

Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients' advanced disease at diagnosis. The NCCN Guidelines for Pancreatic Adenocarcinoma provides recommendations for the diagnosis, evaluation, treatment, and follow-up for patientswith pancreatic cancer. Although survival rates remain relatively unchanged, newermodalities of treatment, including targeted therapies, provide hope for improving patient outcomes. Sections of the manuscript have been updated to be concordant with the most recent update to the guidelines. This manuscript focuses on the available systemic therapy approaches, specifically the treatment options for locally advanced andmetastatic disease.

Original language	English (US)
Pages (from-to)	439-457
Number of pages	19
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	19
Issue number	4
DOIs	https://doi.org/10.6004/jnccn.2021.0017
State	Published - Apr 2021

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2021.0017

Cite this

Tempero, M. A., Malafa, M. P., Al-Hawary, M., Behrman, S. W., Benson, A. B., Cardin, D. B., Chiorean, E. G., Chung, V., Czito, B., Chiaro, M. D., Dillhoff, M., Donahue, T. R., Dotan, E., Ferrone, C. R., Fountzilas, C., Hardacre, J., Hawkins, W. G., Klute, K., Ko, A. H., ... George, G. V. (2021). Pancreatic adenocarcinoma, Version 2.2021. JNCCN Journal of the National Comprehensive Cancer Network, 19(4), 439-457. https://doi.org/10.6004/jnccn.2021.0017

Tempero, MA, Malafa, MP, Al-Hawary, M, Behrman, SW, Benson, AB, Cardin, DB, Chiorean, EG, Chung, V, Czito, B, Chiaro, MD, Dillhoff, M, Donahue, TR, Dotan, E, Ferrone, CR, Fountzilas, C, Hardacre, J, Hawkins, WG, Klute, K, Ko, AH, Kunstman, JW, LoConte, N, Lowy1, AM, Moravek, C, Nakakura, EK, Narang, AK, Obando, J, Polanco, PM, Reddy, S, Reyngold, M, Scaife, C, Shen, J, Vollmer, C, Wolff, RA, Wolpin, BM, Lynn, B & George, GV 2021, 'Pancreatic adenocarcinoma, Version 2.2021', JNCCN Journal of the National Comprehensive Cancer Network, vol. 19, no. 4, pp. 439-457. https://doi.org/10.6004/jnccn.2021.0017

@article{0bebc0c191f54cb8a5d764f168c17709,

title = "Pancreatic adenocarcinoma, Version 2.2021",

abstract = "Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients' advanced disease at diagnosis. The NCCN Guidelines for Pancreatic Adenocarcinoma provides recommendations for the diagnosis, evaluation, treatment, and follow-up for patientswith pancreatic cancer. Although survival rates remain relatively unchanged, newermodalities of treatment, including targeted therapies, provide hope for improving patient outcomes. Sections of the manuscript have been updated to be concordant with the most recent update to the guidelines. This manuscript focuses on the available systemic therapy approaches, specifically the treatment options for locally advanced andmetastatic disease.",

author = "Tempero, {Margaret A.} and Malafa, {Mokenge P.} and Mahmoud Al-Hawary and Behrman, {Stephen W.} and Benson, {Al B.} and Cardin, {Dana B.} and Chiorean, {E. Gabriela} and Vincent Chung and Brian Czito and Chiaro, {Marco Del} and Mary Dillhoff and Donahue, {Timothy R.} and Efrat Dotan and Ferrone, {Cristina R.} and Christos Fountzilas and Jeffrey Hardacre and Hawkins, {William G.} and Kelsey Klute and Ko, {Andrew H.} and Kunstman, {John W.} and Noelle LoConte and Lowy1, {Andrew M.} and Cassadie Moravek and Nakakura, {Eric K.} and Narang, {Amol K.} and Jorge Obando and Polanco, {Patricio M.} and Sushanth Reddy and Marsha Reyngold and Courtney Scaife and Jeanne Shen and Charles Vollmer and Wolff, {Robert A.} and Wolpin, {Brian M.} and Beth Lynn and George, {Giby V.}",

year = "2021",

month = apr,

doi = "10.6004/jnccn.2021.0017",

language = "English (US)",

volume = "19",

pages = "439--457",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "4",

}

TY - JOUR

T1 - Pancreatic adenocarcinoma, Version 2.2021

AU - Tempero, Margaret A.

AU - Malafa, Mokenge P.

AU - Al-Hawary, Mahmoud

AU - Behrman, Stephen W.

AU - Benson, Al B.

AU - Cardin, Dana B.

AU - Chiorean, E. Gabriela

AU - Chung, Vincent

AU - Czito, Brian

AU - Chiaro, Marco Del

AU - Dillhoff, Mary

AU - Donahue, Timothy R.

AU - Dotan, Efrat

AU - Ferrone, Cristina R.

AU - Fountzilas, Christos

AU - Hardacre, Jeffrey

AU - Hawkins, William G.

AU - Klute, Kelsey

AU - Ko, Andrew H.

AU - Kunstman, John W.

AU - LoConte, Noelle

AU - Lowy1, Andrew M.

AU - Moravek, Cassadie

AU - Nakakura, Eric K.

AU - Narang, Amol K.

AU - Obando, Jorge

AU - Polanco, Patricio M.

AU - Reddy, Sushanth

AU - Reyngold, Marsha

AU - Scaife, Courtney

AU - Shen, Jeanne

AU - Vollmer, Charles

AU - Wolff, Robert A.

AU - Wolpin, Brian M.

AU - Lynn, Beth

AU - George, Giby V.

PY - 2021/4

Y1 - 2021/4

N2 - Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients' advanced disease at diagnosis. The NCCN Guidelines for Pancreatic Adenocarcinoma provides recommendations for the diagnosis, evaluation, treatment, and follow-up for patientswith pancreatic cancer. Although survival rates remain relatively unchanged, newermodalities of treatment, including targeted therapies, provide hope for improving patient outcomes. Sections of the manuscript have been updated to be concordant with the most recent update to the guidelines. This manuscript focuses on the available systemic therapy approaches, specifically the treatment options for locally advanced andmetastatic disease.

AB - Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients' advanced disease at diagnosis. The NCCN Guidelines for Pancreatic Adenocarcinoma provides recommendations for the diagnosis, evaluation, treatment, and follow-up for patientswith pancreatic cancer. Although survival rates remain relatively unchanged, newermodalities of treatment, including targeted therapies, provide hope for improving patient outcomes. Sections of the manuscript have been updated to be concordant with the most recent update to the guidelines. This manuscript focuses on the available systemic therapy approaches, specifically the treatment options for locally advanced andmetastatic disease.

UR - http://www.scopus.com/inward/record.url?scp=85103494776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103494776&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2021.0017

DO - 10.6004/jnccn.2021.0017

M3 - Review article

C2 - 33845462

AN - SCOPUS:85103494776

SN - 1540-1405

VL - 19

SP - 439

EP - 457

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 4

ER -

Pancreatic adenocarcinoma, Version 2.2021

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this